Lipocine - LPCN Total Company Value-to-Revenue Ratio

lipocine.com (LPCN) - corporate logo

The enterprise value-to-revenue ratio illustrates the asset's valuation trend, where -1296.79 serves as the current metric level. The success of Lipocine Inc. (LPCN) relies on its oral drug delivery system coupled with strict control over R&D expenditures. This non-cyclical biotech remains resilient to macroeconomic shifts, as demand for the treatment of endocrine pathologies is independent of GDP. Growth is driven by liver drug trials and new patents.

LPCN Lipocine Inc.: Enterprise Value-to-Revenue Ratio in the range 11/23/2025 - 11/20/2026

Lipocine Corporation - analytical breakdowns and key metrics (LPCN)

- share price and expert price forecast:
Initial company analysis:lipocine.com
Flagship merchandise of Lipocine Corp

The stable management of Lipocine Inc. (LPCN), with its successful track record in developing drug delivery systems, provides the foundation for valuing the business via EV/Sales, which measures the company's value excluding debt relative to revenue. By analyzing historical EV/Sales levels on the GURU.Markets platform, an investor can discern real market expectations for the company's earnings, stripped of the influence of capital structure and interest rates.

Competitor analysis

ASND: Enterprise Value-to-Revenue Ratio|MDGL: EV/Sales Multiple|CORT - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Rhythm Corp|Akero Corp (AKRO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio metsera.com (MTSR)|Company Value to Revenue moonlaketx.com MLTX|EV/Sales Multiple CRNX (Crinetics Pharmaceuticals, Inc.)|NAMS: Company Value to Revenue Ratio|SLNO - Enterprise Value-to-Revenue Ratio|Amicus Pharma (FOLD) - Company Value to Revenue|ETNB: EV/Sales Multiple|AGIO - Total Company Value-to-Revenue Ratio|Company Value to Revenue GPCR|Enterprise Value-to-Revenue Multiple MiMedx MDXG|Enterprise Value-to-Revenue Ratio Rezolute Corp (RZLT)|Company Value to Revenue Lexicon Corp LXRX|Enterprise Value-to-Revenue Ratio MBX Biosciences, Inc. MBX|EV/Sales Multiple altimmune.com ALT|AARD - Enterprise Value-to-Revenue Ratio|Sagimet - Enterprise Value-to-Revenue Coefficient|BioAge Labs Inc. (BIOA) - Enterprise Value-to-Revenue Ratio|Enterprise Value to Sales Volume BMEA (Biomea Fusion, Inc.)|QNCX (quincetx.com) - EV/Sales Multiple|GUTS: Business Value to Revenue|Enterprise Value-to-Revenue Ratio vtvtherapeutics.com (VTVT)|ATPC (Agape ATP) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Pluristem Therapeutics PLUR|SYBX: Company Value to Revenue Ratio|MTNB - Enterprise Value-to-Revenue Ratio|Spruce Biosciences, Inc. (SPRB) - Company Value to Revenue|GLTO: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Carmell Corp. (CTCX)|LUMO (Lumos Therapeutics) - EV/Sales Multiple|Organovo Corp (ONVO) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Radius Recycling (RDUS)